Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of methylphenidate and tipepidine. Methylphenidate is a central nervous system stimulant primarily used to treat attention-deficit/hyperactivity disorder (ADHD). It acts as a norepinephrine–dopamine reuptake inhibitor, increasing the synaptic concentrations of these neurotransmitters in the brain, thereby improving attention and reducing hyperactivity and impulsivity[5][7]. Tipepidine is a synthetic, non-opioid antitussive of the thiambutene class that inhibits G protein-coupled inwardly-rectifying potassium channels (GIRKs), which modulates monoaminergic neurotransmission. Tipepidine has been investigated for psychiatric uses including ADHD, where it may enhance dopaminergic signaling without typical stimulant side effects[6][8]. Clinical studies have evaluated this combination for improved efficacy in managing ADHD symptoms compared to methylphenidate alone[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylphenidate + tipepidine.